Version July 2025
Dosage guidance:
Safety: Tincture is 77% alcohol; use caution, do not swallow.
Mouth protectant (for canker sores): Infants ≥6 months, Children, and Adolescents: Topical (oral mucosa): Apply undiluted to affected area not more than every 2 hours.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Benzoin: Drug information")
Mouth protectant: Topical: Apply undiluted to affected area not more than every 2 hours.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Dermatologic: Contact dermatitis (Sasseville 2009)
Dosage form specific issues:
• Alcohol: Tincture is 77% alcohol; use caution.
Other warnings/precautions:
• Self-medication (OTC use): Patients should be instructed to discontinue use and contact health care provider if sore mouth symptoms do not improve in 7 days; rash, swelling, or fever develops; or irritation, pain, or redness worsens or persists.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tincture, External:
Generic: (1 mL, 59 mL, 100 mL, 473 mL, 500 mL, 4000 mL, 20000 mL)
Yes
Topical (mucosa): For topical mucosal use only; avoid contact with eyes; do not swallow. Dry affected area and apply undiluted with cotton swab to canker sore(s).
Topical: For external use only; not for ophthalmic use. Clean and dry affected area prior to use. Apply undiluted with cotton swab to canker sores. Do not swallow.
Store at room temperature. Flammable; keep away from sunlight, heat, fire, or flame.
Protective application for canker sores (OTC: FDA approved in ages ≥6 months and adults).
Note: Approved ages and uses for generic products may vary; consult labeling for specific information.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
There are no known significant interactions.
